Articles tagged with Insulin
A Brazilian study found that children born to obese mothers are more prone to developing metabolic disease due to a lack of the Mfn2 protein in their mother's eggs. This protein regulates mitochondrial function and energy production, leading to abnormal mitochondria shape and dysfunction.
The International Diabetes Closed-Loop (iDCL) Trial found that hybrid closed-loop insulin therapy significantly improved glycemic control in patients with type 1 diabetes. The use of this technology increased Time in Range by 13%, especially during nighttime hours, and reduced time spent at blood glucose levels above 180 mg/dL.
A small, highly controlled study at the National Institutes of Health compared the effects of a low-fat, plant-based diet to a low-carb, animal-based diet on calorie intake, hormone levels, body weight, and more. Participants lost weight on both diets, but only the low-fat diet led to a significant loss of body fat.
The American Diabetes Association has lowered the target HbA1C levels for children with type-1 diabetes to less than 7% to reduce acute and long-term organ damage. The new guidelines aim to improve immediate and long-term health outcomes, fewer complications, and reduced mortality rates in T1D children.
The Endocrine Society recommends government negotiation, greater transparency, and policy changes to reduce insulin costs. These policies aim to increase access to affordable insulin, particularly for low-income individuals and Medicare beneficiaries.
Researchers at NTU Singapore have developed oral insulin nanoparticles that can carry large amounts of insulin, making them a potential alternative to painful injections. The nanoparticles are stable and able to pass through the intestinal wall into the bloodstream, offering a promising solution for diabetic patients.
Scientists have developed advanced imaging techniques to observe pancreatic beta cells packaging insulin and responding to drug treatments. The new methods provide a more complete picture of the cell's functions and components, shedding light on the mechanisms responsible for preventing diabetes.
Researchers from the University of Copenhagen have developed a new insulin molecule that can sense blood sugar levels and release insulin accordingly. This innovative approach aims to reduce the frequency of injections and monitoring required by people with type 1 diabetes, improving their quality of life.
A new study from the University of Eastern Finland found that consuming blackcurrants after a meal can attenuate the rise and fall of blood glucose levels. The beneficial effect is attributed to berry-derived polyphenolic compounds, specifically anthocyanins, which slow down glucose absorption and reduce oxidative stress.
A standardized 'Artificial Pancreas (AP) Dashboard' is proposed to improve glycemic control and reduce hypoglycemia in insulin requiring patients with diabetes. The dashboard provides a single-page report of seven main components, including glucose metrics, insulin management, and user experience.
Researchers discovered a previously unknown way that pancreatic cells decide how much insulin to secrete, pointing to an overlooked enzyme known as pyruvate kinase. Stimulating pyruvate kinase not only increases the secretion of insulin but also has other metabolically protective effects in the liver, muscle and red blood cells.
A study using genome sequencing and CRISPR gene editing tools has uncovered a new biological pathway essential for insulin production in the YIPF5 gene. The research shows that genetic changes in this gene result in high stress levels, leading to cell death in insulin-producing cells.
A recent study suggests that the evolution of insulin has encountered a roadblock, rendering most people vulnerable to Type 2 diabetes. The researchers discovered that even slight variations in the insulin-sequencing process can impair insulin folding and induce cellular stress.
A new study has shown that a minimally-invasive ablation procedure can rejuvenate the lining of the duodenum, leading to significant improvements in blood glucose control and weight loss. In a pilot study, 75% of patients with type 2 diabetes who underwent the procedure were able to discontinue insulin therapy within six months.
A new study by the RAND Corporation found that US insulin prices are significantly higher than those in other high-income countries, even when accounting for rebates and discounts. The average price per unit across all types of insulin in the US is $98.70, compared to a fraction of this cost in other nations.
Researchers at Pennington Biomedical Research Center will investigate how the SGK1 enzyme regulates beta-cell mass when more insulin is needed. The study aims to understand how beta-cell growth mechanisms influence insulin release, potentially leading to new medications for diagnosing and treating metabolic diseases.
A 15-year study found that non-Hispanic white children are more likely to use insulin pumps than non-Hispanic Black children, exacerbating racial disparities in type 1 diabetes outcomes. Researchers emphasize the need for interventions to address these disparities and promote equitable care.
A new study confirms the existence of residual, non-functioning beta cells in living individuals with longstanding type 1 diabetes. Researchers used a non-invasive imaging technique to detect these cells, which may be restored if adequate treatments are available.
A new study reveals that reversing type 2 diabetes can restore the pancreas to a normal size and shape, improving insulin function. After 2 years of weight loss, responders experienced significant growth in pancreas volume and fat reduction, while non-responders showed no change.
A study found that a ferry protein in the pancreas plays a crucial role in regulating insulin levels and protecting against the negative effects of a high-fat diet. The researchers discovered that this protein, VMAT2, helps to shield beta cells from oxidative stress, which can lead to diabetes.
A clinical trial found that a new artificial pancreas system improved blood glucose control in children aged 6-13, achieving 7% daytime improvement and 26% nighttime control. The technology replaces traditional testing and insulin delivery, providing greater convenience and safety.
The study found that youth using the artificial pancreas system had significant improvements in blood glucose control, including a 7% improvement during the daytime and a 26% improvement at night. The technology improved overall time-in-range by nearly 11%, translating to more hours per day in a healthy range.
A genetic variant of the DUSP8 gene impairs brain response to insulin, leading to increased risk of type 2 diabetes. Research reveals protein Dusp8's regulatory effects on hypothalamic insulin sensitivity and inflammatory processes.
Salk Institute scientists develop transplantable human insulin-producing pancreatic cell clusters that evade the immune system, providing sustained blood glucose control without immunosuppressants. The cells were created using stem cell technology and a protein called WNT4 to induce a genetic switch that makes them functional.
Researchers develop a new mouse model of permanent neonatal diabetes using the Kuma mutation, which exhibits severe insulin-deficiency and beta-cell dysfunction in an immune deficient background. The study successfully reverses hyperglycemia with insulin implants, making it suitable for islet transplantation research.
A national cost-sharing cap on insulin can help reduce the financial burden on families of children and young adults with type 1 diabetes. The study found that approximately 60% of patients would benefit from a $25 cap, with average savings of almost $480 per year.
Case studies published by Physicians Committee for Responsible Medicine found that plant-based diets rich in whole carbohydrates improved health markers in individuals with type 1 diabetes. The diets led to decreased insulin needs, stabilized blood sugar control, and reduced cholesterol levels.
A study in Journal of Biological Chemistry describes a new way to determine the age of insulin-storage parcels and sheds light on how their age affects their release into the bloodstream. This finding could help experts better understand diabetes and fine-tune therapies for it.
A new ultra-rapid insulin formulation, UFAL, reached peak activity in pigs with diabetes twice as fast as Humalog, a commercially available option. This could lead to faster quality-of-life improvements for diabetic patients by allowing quicker blood sugar level management during mealtimes.
Stanford researchers developed a new ultrafast insulin formulation that stabilizes monomeric insulin for over 24 hours, allowing it to take effect almost immediately upon injection. The formulation could potentially reduce the time it takes for insulin to reach peak activity by four-fold.
Diabetic ketoacidosis is a common and severe complication in hospitalized patients with COVID-19, causing dehydration and breathing difficulties. A new clinical perspective outlines simpler methods of management to protect healthcare providers and keep ICU beds available for severe cases.
A Phase 2 study led by UB pediatric endocrinologist Teresa Quattrin shows that golimumab, an anti-TNF therapy, preserved beta-cell function and reduced injected insulin required in children and young adults with newly diagnosed Type 1 diabetes. The study demonstrated a higher C-peptide level in patients treated with golimumab compared ...
Researchers at Oregon Health & Science University have developed an AI algorithm that uses data from continuous glucose monitors and wireless insulin pens to provide guidance on adjustments. The algorithm, paired with a smartphone app called DailyDose, generated recommendations in agreement with physicians 67.9% of the time.
The study shows that the FreeStyle Libre 14 day system is estimated to save roughly 50% in average costs associated with severe hypoglycemia for people with type 1 and type 2 diabetes. Annual cost savings are 61% and 63% lower compared to traditional fingerstick testing.
A new study finds that people with Type 1 diabetes spend an average of $2,500 a year on healthcare costs, with diabetes-related supplies costing more than insulin. The study also highlights the importance of automating glucose monitoring and insulin delivery for young children and adolescents with Type 1 diabetes.
Researchers created a mini-insulin molecule that combines human insulin's potency with the fast-acting potential of cone snail venom, potentially improving blood sugar control. The hybrid insulin has the same potency as human insulin but acts faster, making it a prime candidate for new diabetes treatments.
Researchers at ETH Zurich create implant that uses electrical signals to stimulate insulin production in diabetic mice, offering potential breakthrough for real-time glycemic control. The system is designed to be connected to the internet and controlled via an app, paving the way for a more integrated approach to diabetes management.
Researchers have developed a wearable device that uses external electric fields to trigger insulin release from bioengineered cells, stabilizing blood glucose levels in mice. The approach opens the door for remote-controlled diabetes therapies and represents an expansion of electrogenetic toolboxes for human therapeutics.
A study revealed that insufficient insulin action in adipocytes leads to the development of diabetes and NASH by hyperactivating the protein FoxO1. This finding could serve as a potential target for new drug development for these conditions.
Researchers developed a novel approach to decontaminate single-cell RNA seq data, allowing for accurate quantification of cell-specific drug effects in pancreatic islets. The method revealed species-specific and cell-type-specific responses to drugs, including the induction of insulin production in alpha cells.
A study funded by JDRF, ADA, and Helmsley found all human and analog insulins in US pharmacies contained the expected amount of active insulin, posing no safety risks for people with diabetes.
Researchers at Stanford University have developed a way to combine insulin with amylin, a second hormone that plays a synergistic role in controlling blood sugar levels. The new technique involves a protective coating that allows the two hormones to coexist in a single shot, enabling patients to take a double-acting injection.
Researchers found that patients with type 2 diabetes have blood vessels resistant to insulin, leading to elevated oxidative stress and vessel dysfunction. A new therapy combining insulin treatment with DPP4 inhibitors shows promise in reversing damaging vascular effects.
Two case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in adults and infants during the pandemic. The technology showed improved outcomes with increased time-in-range, as patients received virtual management and dose adjustments.
Type 2 diabetes patients exhibit elevated glucagon levels due to α-cell resistance to insulin. Glucagon counteracts insulin's effects, exacerbating high blood sugar levels.
A new study finds that a wearable device called V-Go can safely deliver regular human insulin (RHI) to patients with type 2 diabetes, achieving good blood sugar control. The study, which compared RHI to rapid acting insulin (RAI) analogs, showed improvements in hemoglobin A1c levels and met its primary endpoint of noninferiority.
A recent study found that technology use by adults with type 1 diabetes is lower among African-American and Hispanic patients. The use of continuous glucose monitors (CGM) and continuous subcutaneous insulin infusion (CSII) devices was significantly lower in these groups, highlighting racial disparities in access to healthcare.
A study analyzing 6 million days of real-world data shows the MiniMed 670G system can maintain target glucose range of 70-180 mg/dL over 71% of the time. The AutoMode feature improves glycemic control, reducing low and high blood sugar episodes.
Researchers at MIT have developed a way to encapsulate therapeutic cells in a flexible protective device that prevents immune rejection while allowing oxygen and nutrients to reach the cells. This technology could lead to long-term treatment of chronic diseases such as diabetes.
A team of international medical experts successfully delivered insulin via a drone to a patient living in a remote community in Ireland, addressing healthcare access issues. The project demonstrated the potential for autonomous drones to deliver life-saving medications and supplies in disaster scenarios.
Researchers at UW-Madison discovered that removing a specific gene from insulin-producing cells can prevent Type 1 diabetes in mice by allowing the cells to disguise themselves from immune cells. This genetic manipulation enabled the cells to evade an autoimmune response, leading to normal glucose levels and insulin production.
Research reveals that children diagnosed with type 1 diabetes under 7 years old have a different form of the condition compared to those diagnosed at 13 or above. The study proposes two distinct endotypes: T1DE1 and T1DE2, which could lead to new treatments and a potential cure for some people.
Researchers developed a mathematical model to predict the behavior of glucose-responsive insulins in humans and rodents. The model identified optimal designs that could work well in both species, with about 13% predicted to be effective in both, and 14% in humans alone.
A team of McGill University researchers has created an artificial pancreas system that significantly improves glucose control, enhancing quality of life for individuals with type 1 diabetes. The system, which combines insulin and pramlintide, has shown promising results in minimizing glucose highs and lows.
Researchers found a truncated receptor called DAF-2B that acts as a decoy to capture insulin molecules, reducing insulin signaling. This discovery may offer new insights into insulin resistance, a feature of type 2 diabetes and aging.
A new study by Brigham and Women's Hospital finds that over 40% of patients refuse insulin therapy, leading to worse blood sugar control and longer time to lower blood sugar levels. Patients who decline insulin therapy had more severe diabetes complications and higher blood sugar levels.
A new study found that people with Type 2 diabetes in the US often receive treatment that is too aggressive or not aggressive enough, with those who are most likely to benefit from intensive therapy being underserved. The study suggests a fine line between effective treatment and increased risk of hypoglycemia.
Boston College biologist Emrah Altindis received a $300,000 grant from the G. Harold and Leila Y. Mathers Foundation to explore the role of gut microbes and viruses in triggering Type 1 diabetes. The research aims to understand molecular mimicry as a potential cause of the autoimmune disease.
A new device can automatically manage glucose levels and deliver needed insulin quickly, eliminating the need for constant blood sugar checks and insulin injections. The adhesive patch, about the size of a quarter, has been successfully tested on mice and pigs, showing promise as a potential diabetes treatment.
Researchers at the University of Illinois found that tasting or consuming sucralose can affect blood glucose and insulin levels, even in healthy individuals. The study suggests that sweetness should be consumed in moderation regardless of calories.